Summary
StartUp Health community member Chris Mirro, Chief Growth Officer of Veravas, discusses their innovative active tau blood test for early Alzheimer's detection. This test measures active tau pathology, a key Alzheimer's marker, even before clinical symptoms appear. The test, launched in May 2025, achieved a 96% agreement with tau PET in studies and gained global recognition. Veravas is seeking to build partnerships with pharmaceutical companies and expand its role in clinical trials.
Highlights
🧠 Active Tau Blood Test for Alzheimer’s: Veravas' test measures active tau pathology, which is a key Alzheimer's marker, offering early detection before clinical symptoms appear.
🎯 Major Milestone: The test was launched in May 2025 as a laboratory-developed test, marking a significant achievement for Veravas.
📊 96% Agreement with tau PET: The test demonstrated a 96% agreement with tau PET in studies, confirming its accuracy and effectiveness.
🌍 Global Recognition: Veravas gained global recognition at the AAIC conference, helping to raise awareness of their innovative approach to Alzheimer’s detection.
🤝 Partnerships and Collaborations: Veravas aims to build partnerships with large pharmaceutical companies, particularly for clinical trials and diagnostics, to expand their reach and capabilities.
💡 Alzheimer’s Moonshot: Being part of the Alzheimer’s Moonshot Community has helped Veravas connect with experts, strengthen their network, and address key challenges in early Alzheimer’s detection.
Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world’s biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is available to StartUp Health Members. If you’re mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit.
👉 Learn more and join today.
